Literature DB >> 24461017

Atomic level rendering of DNA-drug encounter.

Maria F Lucas1, Israel Cabeza de Vaca1, Ryoji Takahashi1, Jaime Rubio-Martínez2, Víctor Guallar3.   

Abstract

Computer simulations have been demonstrated to be important for unraveling atomic mechanisms in biological systems. In this study, we show how combining unbiased molecular dynamic simulations with appropriate analysis tools can successfully describe metal-based drug interactions with DNA. To elucidate the noncovalent affinity of cisplatin's family to DNA, we performed extensive all-atom molecular dynamics simulations (3.7 μs total simulation length). The results show that the parent drug, cisplatin, has less affinity to form noncovalent adducts in the major groove than its aquo complexes. Furthermore, the relative position in which the drugs enter the major groove is dependent on the compound's net charge. Based on the simulations, we estimated noncovalent binding free energies through the use of Markov state models. In addition, and to overcome the lack of experimental information, we employed two additional methods: Molecular Mechanics Poisson-Boltzmann Surface Area (MMPB-SA) and steered molecular dynamics with the Jarzynski estimator, with an overall good agreement between the three methods. All complexes show interaction energies below 3 kcal/mol with DNA but the charged hydrolysis products have slightly more favorable binding free energies than the parent drug. Moreover, this study sets the precedent for future unbiased DNA-ligand simulations of more complex binders.
Copyright © 2014 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24461017      PMCID: PMC3907256          DOI: 10.1016/j.bpj.2013.11.4494

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  62 in total

1.  Unrestrained 5 ns molecular dynamics simulation of a cisplatin-DNA 1,2-GG adduct provides a rationale for the NMR features and reveals increased conformational flexibility at the platinum binding site.

Authors:  M A Elizondo-Riojas; J Kozelka
Journal:  J Mol Biol       Date:  2001-12-14       Impact factor: 5.469

2.  Hydrolysis theory for cisplatin and its analogues based on density functional studies.

Authors:  Y Zhang; Z Guo; X Z You
Journal:  J Am Chem Soc       Date:  2001-09-26       Impact factor: 15.419

3.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

4.  Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile.

Authors:  Ga Young Park; Justin J Wilson; Ying Song; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

5.  EMMA: A Software Package for Markov Model Building and Analysis.

Authors:  Martin Senne; Benjamin Trendelkamp-Schroer; Antonia S J S Mey; Christof Schütte; Frank Noé
Journal:  J Chem Theory Comput       Date:  2012-06-18       Impact factor: 6.006

6.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

7.  Bifunctional binding of cisplatin to DNA: why does cisplatin form 1,2-intrastrand cross-links with ag but not with GA?

Authors:  Yogita Mantri; Stephen J Lippard; Mu-Hyun Baik
Journal:  J Am Chem Soc       Date:  2007-04-03       Impact factor: 15.419

Review 8.  Biomolecular simulation: a computational microscope for molecular biology.

Authors:  Ron O Dror; Robert M Dirks; J P Grossman; Huafeng Xu; David E Shaw
Journal:  Annu Rev Biophys       Date:  2012       Impact factor: 12.981

9.  Which one among the Pt-containing anticancer drugs more easily forms monoadducts with G and A DNA bases? A comparative study among oxaliplatin, nedaplatin, and carboplatin.

Authors:  Marta E Alberto; Valeria Butera; Nino Russo
Journal:  Inorg Chem       Date:  2011-06-24       Impact factor: 5.165

10.  Conformational analysis of nucleic acids revisited: Curves+.

Authors:  R Lavery; M Moakher; J H Maddocks; D Petkeviciute; K Zakrzewska
Journal:  Nucleic Acids Res       Date:  2009-07-22       Impact factor: 16.971

View more
  2 in total

Review 1.  Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments.

Authors:  Rao Khalid Mehmood
Journal:  Oncol Rev       Date:  2014-09-23

Review 2.  Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective.

Authors:  Rao Khalid Mehmood; Jody Parker; Shakil Ahmed; Eyas Qasem; Ahmed A Mohammed; Muhammed Zeeshan; Ernest Jehangir
Journal:  World J Oncol       Date:  2014-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.